CBI Scene Blog

INFOGRAPHIC: Seizing a Rare Opportunity- A Current Snapshot of the Rare Disease Community

Posted by Logan Fleck on Sep 25, 2014 9:00:00 AM

People living with rare diseases face unique obstacles that stand in the way of their treatment. Because a rare disease affects less than 200,000 Americans, these diseases can go largely unrecognized – even amongst health care providers. Technological developments and the expansion of online communities are helping to raise awareness by providing new opportunities for networking and valuable resources for patients and professionals alike.

Tracking down participants for clinical trials can be difficult and trials often occur far from patients’ homes, but drug developers are beginning to use online sharing and social media to spread the word to target communities. Individuals within these communities are also spreading the word and helping to increase involvement in trials where new treatments are in high demand. Because only about 400 approved treatments exist for rare diseases, there is pressure for new medicines to be produced quickly and most development timelines are condensed. The drugs that meet FDA criteria are released and provide great relief to a small market. However, the shortened timeline can increase the opportunity for error to occur outside of the trial and limits the amount of time for observations to ensure a drug’s maximum efficacy.

Read More

Topics: Commercial & Patient Programs, Patient Access, Patient Assistance, Rare Disease & Orphan Drugs

The Major Barriers of Entry for Therapeutic Discoveries for Rare Disease Conditions

Posted by Natalie R on Sep 24, 2014 11:36:03 AM

Contrary to what its name implies, rare diseases are anything but rare. According to NCATS, 25-30 million people in the United States suffer from rare diseases, which averages out to about 1 in 10 Americans. Worldwide, an estimated 350 million people are living with rare diseases. The terminological disconnect can be explained by the approximately 7,000 different types of rare diseases and orphan disorder—a staggering figure that is growing every day. 

Clearly, there's a high demand for cultivating research and treatments for rare diseases. So what's standing in the way?

Read More

Topics: Commercial & Patient Programs, Patient Access, Patient Assistance, speed to therapy, Rare Disease & Orphan Drugs

5 Initiatives to Advance Research into Rare Disease Therapies

Posted by Linda K on Aug 28, 2014 11:45:00 AM

Rare diseases have traditionally received far less attention from legislators, researchers and pharmaceutical companies than more prevalent health issues. Rare diseases have often been overlooked because of a myraid of reasons including: lack of research on the disease state, difficulty in finding and retaining patients to participate in clinical trials, getting coverage approvals from payers, spreading market awareness about the disroder, and the financial return of such therapies.

Read More

Topics: Commercial & Patient Programs, Patient Access, Patient Assistance, Clinical, Rare Disease & Orphan Drugs

An Analysis on Effectiveness Evidence in FDA's Approval of Orphan Drugs

Posted by Stephanie V on Jun 20, 2014 2:08:00 PM

 

The FDA has a commitment to getting products to treat orphan diseases on the market as quickly as possible. Some of the people who have these diseases have no o

ther options for treatment, and a new drug could offer them their only hope of survival.

Read More

Topics: patient adherence, Patient Access, Patient Assistance, Rare Disease & Orphan Drugs

eCoupons Offer Adherence and Patient Engagement Opportunities

Posted by Ken Kark on Jun 13, 2014 11:25:00 AM

McKesson Patient Relationship Solutions (MPRS) is pleased to have been named a finalist in the 9th Annual Strategic Patient Adherence Awards, dedicated to recognizing excellence and advances in patient adherence. In advance of the Patient Adherence and Access Summit (PAAS), we wanted to preview the “Coupon Integration and Tracking within e-Prescribing Workflow” program, which was designed to provide brands with co-pay offset programs delivered through physicians’ e-Prescribing/EHR systems to patients at the point of prescribing.

Read More

Topics: Brand & Digital Strategy, patient adherence, Patient Access, Patient Assistance

INFOGRAPHIC: Innovations in Oncology Therapy & Research

Posted by Lucy Weiland on Dec 9, 2013 11:19:00 AM

By the end of 2013, nearly 1.7 million Americans will have been diagnosed with cancer. Global cancer mortality rates may grow from 12.8 million in 2008 to 22.2 million in 2030…  but our future is looking brighter thanks to oncology innovation. More Americans are surviving cancer: the prediction for 2012 cancer survivors was 12 million, but we exceeded that by almost 2 million additional survivors. With these advancements, we’re fighting back. We’re making incredible strides in cancer treatment. Oncology is a growing field with many notable successes, and it shows promise in increasing cancer survival rates and finding a real cure.

Read More

Topics: Infographics, oncolytics, Commercial & Patient Programs, Patient Access, Patient Assistance

Harry Potter’s Severus Snape & Big Pharma, a Comparison

Posted by Daria Binder on Sep 18, 2013 11:25:00 AM

Read More

Topics: Pharma Accounting & Reporting, Compliance & Regulatory, Brand & Digital Strategy, Pharma Marketing, Commercial & Patient Programs, Accounting and Contract Operations, Medical Affairs & Communication, pharma responsibility, Patient Access, Patient Assistance, Distribution and Channel

Need for Speed: A Chat with Joel W. Beetsch of Celgene

Posted by Lauren Acquadro on Jul 24, 2013 9:03:00 AM

The delays in time to first fill are steadily increasing—keeping patients from necessary medications. The path to script includes a variety of stakeholders and channels working together to deliver the product to the customer; however, streamlining and coordinating this process can prove challenging.

Read More

Topics: Patient Access, Patient Assistance

Challenging Pharma’s “Bad Rep”

Posted by Emily Forest on Jul 12, 2013 10:00:00 AM

Read More

Topics: pharma responsibility, Patient Assistance

How Healthcare Reform Will Affect Your Patient Assistance Strategy

Posted by Amanda Batstone on Mar 1, 2013 1:54:00 PM

Read More

Topics: Commercial & Patient Programs, Healthcare Reform, Patient Access, Patient Assistance